For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Planned EDC/Rave Upgrade

Starting Sunday, March 29th, 2020 beginning at 8:00 AM EDT, and ending on Sunday, March 29th, 2020 beginning at 12:30 AM EDT. During this time there will be no access to the EDC/Rave system. Please share this notification to the personnel who will be affected by this within your organization. Maintenance Start: Sunday, March 29th, 2020 at 8:00 AM EDT. Maintenance End: Sunday, March 29th, 2020 at 12:30 AM EDT.
We are sorry for any inconvenience this may cause.

Dr. Quincy Chu, MD, FRCP(C)

Dr. Quincy Chu – Incoming CCTG Investigational New Drug Committee Chair
Incoming CCTG Investigational New Drug Committee Chair

Dr. Quincy Chu – Incoming CCTG Investigational New Drug Committee Chair

Dr. Quincy Chu is a medical oncologist who specializes in thoracic malignancies as well as early phase clinical trials. He received his M.D degree from University of Toronto in Ontario, Canada. He is an investigator with the Cross Cancer Institute’s New Drug Development Program, and is also the incoming CCTG Investigational New Drug Committee Chair.

“Canadian researchers working together on CCTG collaborative clinical trials get novel and effective,
therapy to the patient faster, learn from each other and then achieve even more.”

Research Interests:

  • Thoracic malignancies and sarcomas
  • Phase I/II clinical trials of innovative anti-cancer agents
  • Molecular determinants of response and toxicities of innovative anti-cancer agents;

Publications

  • Not all publications available on PubMed

CCTG Investigational New Drug Committee